NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
Sellas Life Sciences Group
Ludwig Institute for Cancer Research
Marker Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Washington
Massachusetts General Hospital
University of Virginia
M.D. Anderson Cancer Center